A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

You likely can't join if

• Patient has received daratumumab or any other drug specifically targeting CD38 previously.
• Patient’s disease shows evidence of refractoriness or intolerance to lenalidomide. If previously treated with a lenalidomide-containing regimen, the patient is excluded if he or she: a) Discontinued due to any AEs related to prior lenalidomide treatment, or b) If, at any time point, the patient was refractory to any dose of lenalidomide.
• Patient has received a prior treatment with one or more of the followings: a) Approved anti-myeloma agents within 14 days or 5 PK half-lives of the treatment, whichever is longer, before the date of randomization. Note. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum 4 days) before Day 1 of Cycle 1. b) Current or recent treatment (within 28 days before randomization or 5 half-lives, whichever is longer) with any other investigational medicinal product or device. c) Radiation therapy within 14 days of randomization. Patients must have recovered from all radiation-related toxicities. d) Plasmapheresis within 28 days of randomization. e) Live or live-attenuated vaccine, or all coronavirus disease-19 (COVID-19) vaccines within 14 days prior to randomization.
• Patient has received ASCT within 12 weeks before the date of randomization, or the patient’s immune system has not sufficiently recovered after ASCT under the investigator's judgment.
• Patient has previously received an allogenic stem cell transplant regardless of timing.